Best Sustainability Tech Companies in Jiangsu, China
The 36 best Sustainability Tech companies in Jiangsu, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Abogen Biosciences.
Our analysis of 293 Sustainability Tech companies
$38.4b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Sustainability Tech companies in Jiangsu
| # | Company | Last round | Disclosed funding | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Aidea Provides multiple of bio-similar drugs and GMP services | — | — | Public | — | 421 | — | — | — |
| 2 | BioHermes Provider of POC diagnostic devices and kits | — | — | Funding Raised | Zhen Lei Founder & CEO | — | UIKitNginxjQuery UI+6 | — | — |
| 3 | C4X Technologies Provider of technology to convert carbon into fuel and products | — | — | Unfunded | Wayne Song CEO | 23 | — | — | — |
| 4 | Changzhou Almaden Thin-film solar PV panels and utility-scale project developer | — | — | Public | — | 773 | — | 38 patents Advanced curved laminated glass manufacturing and perovskite‑silicon tandem photovoltaic glass solutions | — |
| 5 | DALEN Provider of app-based smart LED-lighting solutions | — | — | Funding Raised | — | 122 | — | — | — |
| 6 | First O-Lite OLED lighting panels and products manufacturer | — | — | Deadpooled | Jin-Shan Wang Founder & CEO | — | — | — | — |
| 7 | Ginkgo Pharma Chinese, clinical-stage biopharma developing targeted Hepatitis C virus NS3 protein inhibitors | — | — | Funding Raised | Chen li Owner | — | — | — | — |
| 8 | Jiangsu Lixing Power Electronics Technology Provider of LED lighting solution | — | — | Unfunded | Chang Qian Founder | — | — | — | — |
Top 12 Sustainability Tech companies in Jiangsu
#1
Series B · Suzhou, Jiangsu · founded 2021$22.1Mraised▾
Developer of RNA-based drugs for multiple diseases. The company focuses on the development of innovative drugs and vaccines with RNA as the core for infectious diseases, tumor immunology, and metabolic diseases.
- Oct 2025Series B$44M
- May 2022Series A$22.1M
- Dec 2021Angel—
#2
Series C · Suzhou, Jiangsu · founded 2019$1.1Braised▾
Developer of mRNA-based therapeutics for cancer and infectious diseases. The company has developed proprietary technology platforms in mRNA design, in vitro synthesis, and LNP-based delivery systems to develop targeted therapies for infectious and immuno-oncology indications.
- May 2022Series C—
- Nov 2021Series C$300M
- Aug 2021Series C$720M
- Apr 2021Series B$91.6M
#3
Series E · Suzhou, Jiangsu · founded 2017$97.3Mraised▾
Developer of therapeutics for multiple diseases. It offers a drug pipeline that includes BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and antibody-drug conjugates for the treatment of cancer, infectious disease, and metabolic disease.
- Feb 2024Series E$97.3M
#4
Public · Suzhou, Jiangsu · founded 2007 · 228 employees$200.8Mraised▾
Developer of nucleic acid drugs based on RNA interference (RNAi) technology. The company focuses on RNAi technology, drug discovery, siRNA design and screening, chemical modification, delivery technology, PD/PK study, safety evaluation, clinical trial, and other related aspects. Also, offers siRNA therapeutics against Hepatitis B, breast carcinoma, liver fibrosis, liver carcinoma, HIV, etc.
- Jul 2022Series E$40M
- Apr 2020Series C$66.2M
- Dec 2019Series C$28.8M
- Mar 2017Series B$39.1M
#5
Public · Suzhou, Jiangsu · founded 2008 · 3918 employees$210.5Mraised▾
Manufacturer of solar cells and solar PV panels
- Jan 2018Post IPO$210.5M
#6
Seed · Suzhou, Jiangsu · founded 2021$14.6Mraised▾
Developer of nucleic acid drugs to treat various diseases. The company focuses on the research and development of innovative ribonucleic acid (RNA) drugs for infectious diseases, cancer, and metabolic conditions.
- Mar 2023Seed$14.6M
#7
Public · Suzhou, Jiangsu · founded 2010 · 488 employees$36.5Mraised▾
Developer of NGS-based diagnostic solutions for neonatal. The company has a range of pre-pregnancy tests, pre-implantation tests, non-invasive prenatal tests, and early/neonatal genetic screening tests, all marketed under the Basecare brand. The company is supported by Daan Gene Corp. of Sun Yat-Sen University.
- May 2020Series C$21.1M
- Sep 2017Series B$15.4M
- Series A—
#8
Series C · Nanjing, Jiangsu · founded 2002 · 392 employees$43.2Mraised▾
Frontier Biotechnologies is engaged in discovery, development and manufacturing peptide API and finished products. Its lead product candidate, Albuvirtide, is an HIV fusion inhibitor for the treatment of HIV infection and AIDS. Other products include a transdermal patch for musculoskeletal pain. The company also provides services for peptide synthesis (from mg to 100 kg), process development, analytical method development, CMC studies, GMP manufacturing for clinical supply.
- Dec 2016Series C$43.2M
#9
Series A · Wuxi, Jiangsu · founded 2018 · 70 employees$11.1Mraised▾
Provider of commercial weather solutions integrating supercomputing, simulation, and AI. The company delivers solutions for commercial weather, intelligent environmental protection, smart agriculture, and smart energy. It also serves transportation, shipping, disaster prevention, smart cities, and financial insurance sectors. The company’s core technology is an intelligent weather forecasting platform. This platform combines big data, artificial intelligence, and numerical simulation.
- Jul 2021Series A$7.7M
- Jan 2021Seed$3.4M
#10
Series D · Wuxi, Jiangsu · founded 2009—raised▾
Jiangsu Pulai Pharmaceutical Biotechnology develops an anti-microbial drug based on peptides. The company is involved in research and development of products like Ply Pharmaceutical 1.1, PL-5, antibacterial peptide antipruritic composition and its application, anti-fungal drugs PL-18, antibacterial peptide eye drops PL-33 and anti-tumor peptide small molecule drugs PL-AC among others. The company is also involved in the development of several generic medicines.
- Jan 2026Series D—
#11
Seed · Suzhou, Jiangsu · founded 2023—raised▾
AdvanSol Power Technology specializes in micro-string inverters for solar systems, aiming to break the overseas monopoly and fill the domestic gap in the market. Their focus is on providing advanced solutions for photovoltaic power stations with their cloud platform integration.
- Oct 2025Seed—
- Jun 2024Angel—
#12
Public · Suzhou, Jiangsu · founded 2009 · 97 employees—raised▾
Developer of therapeutics to treat cancer and other diseases. The company focuses on developing therapeutics that inhibit protein interactions to restore apoptosis, or programmed cell death. The company develops pipeline of therapeutics for cancers, chronic hepatitis B, and age-related diseases.
- Jun 2024Post IPO—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Sustainability Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Jiangsu researches in climate adaptation
- Jiangsu University6
- Jiangsu Center for Collaborative Innovation in Geographical Information Resource Development and Application3
- Government of Jiangsu Province1
- Jiangsu Provincial Urban Planning and Design Institute1
- Jiangsu Provincial Academy of Forestry Science and Management1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.